Calliditas Therapeutics AB is predicting strong sales growth this year for its immunoglobulin A nephropathy (IgAN) treatment, Tarpeyo, despite the imminent arrival on the market of Travere Therapeutics, Inc.'s just-approved Filspari therapy.
The Swedish biotech is predicting 2023 sales of Tarpeyo, an oral formulation designed to release the steroid budesonide into the gut, of between $120-150m. The forecast comes after Calliditas revealed that sales of the drug reached SEK372.2m ($36.8m) for the first 11 months of commercialization after receiving accelerated approval from the US Food and Drug Administration for Tarpeyo for IgAN, a rare kidney disease, in December 2021
